Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

PBMBullishCorporate Developmentsnews

High materiality7/10

PBM advances U.S. ibogaine supply via Benuvia manufacturing partnership

Oct 5, 2026, 7:18 AM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

The partnership enhances U.S. manufacturing capabilities and regulatory positioning; potential revenue/partnership upside via PsyLabs license, but execution risk remains around quotas and definitive agreement timing.

AI summary

What happened, with direct paths to the underlying reporting

Psyence BioMed's TIRC signed a manufacturing services agreement with Benuvia to produce pharmaceutical-grade ibogaine API in the U.S., tying into a forthcoming exclusive supply deal with PsyLabs. With a DEA-registered 83,000-square-foot Round Rock facility and active quota discussions, the venture aims to establish a compliant, domestic supply chain to support future regulatory programs. Key catalyst: definitive agreement by Nov 30, 2026.

PBM's TIRC signs U.S. ibogaine API manufacturing pact with Benuvia.
Benuvia operates an 83,000 sq ft DEA-registered facility in Round Rock.
Definitive PsyLabs agreement to be concluded by Nov 30, 2026.
Strategy aims to create end-to-end U.S. ibogaine supply.
Quotas and regulatory approvals remain key timing constraints.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.